FDA Clears CliniComp PACS Viewer (MIMPS), Unifying Diagnostic Imaging, Enterprise EHR, and Native AI in a Single Platform

FDA Clears CliniComp PACS Viewer (MIMPS), Unifying Diagnostic Imaging, Enterprise EHR, and Native AI in a Single Platform

Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Engineering, Cybersecurity and AI

ECI has announced the appointment of Taranjit S. Samra, DRSc, MSEE, RAC, as Head of Medical Device Software Engineering, Cybersecurity and AI.

Siddharth Mittal Appointed as Managing Director & CEO of Syngene International

eClinical Solutions Advances Risk-Based Quality Management Solutions, Helping Sponsors Meet ICH E6(R3) Regulatory Guidelines

Enhancements further break down silos and reduce fragmentation through integrated risk and quality management within one clinical data intelligence platform

Sunnen Products Company Highlights the PGE-6000 Gage with Advanced Precision for Medical Applications

Cutting-Edge Bore Gaging System Offers Unmatched Precision, Versatility, and Efficiency for High-Precision Measurement Needs in Medical Device Manufacturing

Symeres and Axxam Appoint Russell Thomas as Chief Scientific Officer to lead their collaborative integrated discovery platform

Terrestrial Doses First Patients in Phase 1 Clinical Trial of Tacterra™ Microarray Patch for Semaglutide Delivery

Terrestrial Bio, Inc., a biotech company transforming the delivery of next-generation therapies, today announced it has dosed its first patients in the company's Phase 1 clinical trial evaluating VX-201, a needle-free microarray patch (MAP) that delivers semaglutide.

ZoBio launches comprehensive DEL hit discovery service for challenging targets

Veeva Introduces New EHS Application for Proactive Risk Management and Intelligent Automation

Aylward Enterprises Highlights Cube Feed System for High-Speed Solid-Dose Blister Packaging

Servo-driven blister feed technology delivers precise product placement, flexible format handling, and seamless integration with continuous and intermittent blister machines

Revecore Launches ReClaim(TM), an AI-Native Platform Built for the Complexity Modern Hospitals Face

Ambience Healthcare Introduces Nursing Suite to Extend System of Intelligence Across Inpatient Nursing

ZeOmega Earns HITRUST CSF® Certification through DirectTrust®

Eli Lilly Launches National Sleep Apnea Awareness Campaign with Shaquille O'Neal and Zepbound

Eli Lilly has launched a nationwide awareness campaign featuring basketball legend Shaquille O'Neal to highlight the risks of moderate-to-severe obstructive sleep apnea (OSA). After learning that years of fatigue, loud snoring, and poor sleep were symptoms of OSA, O'Neal began treatment with Zepbound® (tirzepatide). The campaign encourages people experiencing sleep apnea symptoms to seek medical advice and explore treatment options. Zepbound is the first FDA-approved prescription medicine for adults with obesity and moderate-to-severe OSA, helping improve sleep quality and reduce breathing interruptions during sleep.

Watchmaker Launches New Technologies Addressing NGS Workflow Bottlenecks and Sequencing Accuracy Challenges

Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer

Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies

Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomics to Compound Screening Scale

New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates

FDA Reopens Path for UniQure’s AMT-130: 3 Years of Gene Therapy Data Could Support Huntington’s Disease Approval

UniQure plans to submit its Huntington’s disease gene therapy, AMT-130, for FDA approval after reaching agreement with the agency on using three years of clinical data. The therapy demonstrated a 75% slowdown in disease progression among patients receiving the higher dose. The development marks a major shift in the FDA’s stance following recent leadership changes and is being viewed as a positive signal for the broader cell and gene therapy sector. Following the announcement, UniQure shares surged nearly 80%, reflecting renewed investor confidence in the program and its regulatory pathway.

Spot Biosystems Launches with $40 Million Funding and Breakthrough Non-Viral Gene Therapy for DMD

Spot Biosystems has emerged from stealth with $40 million in funding and a breakthrough non-viral gene therapy platform for Duchenne muscular dystrophy (DMD). The company demonstrated the world's first successful delivery of full-length dystrophin to human skeletal muscle using engineered extracellular vesicles (EVs). Early clinical data showed dystrophin increases of over 1,000% and 2,000% in two pediatric DMD patients, along with improved muscle function. The technology aims to overcome the limitations of traditional viral gene therapies by enabling repeat dosing and larger genetic payload delivery.

Proscia Launches Fifth Generation of Concentriq, Bringing the Latest Advancements in AI to Pathologists and Scientists

Built on a new AI-native architecture, Concentriq delivers clinically and scientifically grounded intelligence to decisions throughout drug discovery, development, and case review